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Observational studies support a neuroprotective role of hormone therapy (HT) in the perimenopause,
with hippocampal size being a widely used biomarker. We investigated the effect of HT started before the
onset of menopause and lasting for at least 3 years on hippocampal volume and shape in 80 post-
menopausal women and 80 controls matched on age and intracranial volume taken from a large
community-based sample (Nord-Trøndelag Health Studyemagnetic resonance imaging). The main effect
of hormone group showed a statistically signiﬁcant difference in hippocampal volumes (p ¼ 0.028). Both
the right (3.2%) and left (2.8%) hippocampal volumes were larger in the HT group but only signiﬁcant for
the right hippocampus (p ¼ 0.023). Shape analysis revealed signiﬁcant regional sparing of the medial
aspect of the right hippocampal head and lateral aspect of the body extending to the tail, corresponding
to the cornu ammonis, including part of the subiculum, in the HT group. A similar nonsigniﬁcant pattern
was observed in the left hippocampus. The present study provides support for the critical window theory
demonstrating that HT initiated in the perimenopause has neuroprotective properties.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Whether hormone therapy (HT) has the potential to reduce the
risk of dementia and Alzheimer’s disease (AD) in women continues
to draw debate. Despite convincing evidence from several human
observational studies (Kawas et al., 1997; Shao et al., 2012; Tang
et al., 1996; Whitmer et al., 2011; Zandi et al., 2002), 2 large ran-
domized controlled trials (RCTs), the Women’s Health Initiative
Memory Study (WHIMS) and the Heart and Estrogen/Progestin
Replacement Study, found poorer cognitive performance (Espeland
et al., 2004; Grady et al., 2002; Rapp et al., 2003) and increased risk
of developing dementia (Shumaker et al., 2003) inwomen that used
HT. Several methodological differences are suggested to explain the
discrepant results between observational and clinical trials,
including differences in HT formulation, dosage, cyclic versus
continuous hormone delivery and timing of HT administration in
relation to menopause (Fischer et al., 2014; Maki and Henderson,
2012). The importance of the timing of HT in relation to meno-
pause may be particularly relevant. Indeed, the critical window
theory proposes that only HT initiated around the onset ofcience, Faculty of Medicine,
U), 7489 Trondheim, Norway.
).
Inc. This is an open access article umenopause has neuroprotective effects (Marder and Sano, 2000;
Resnick and Henderson, 2002). The WHIMS and Heart and Estro-
gen/Progestin Replacement Studies included women who were
much older and started HT many years after menopause, in whom
positive effects of HT are not expected according to the critical
window theory. Although there are several observational studies
that support the critical window theory (Shao et al., 2012; Whitmer
et al., 2011), a recent meta-analysis of HT trials on cognition was
unable to provide evidence for a speciﬁc effect of HT treatment
started before menopause as opposed to later (Hogervorst and
Bandelow, 2010). No effect of age, initiation perimenopausally or
postmenopausally, nor duration of HT affected the cognitive
outcome (Hogervorst and Bandelow, 2010). However, based largely
on the WHIMS study, there is strong evidence to support that HT
initiated at age 65 years or older increases dementia risk (Maki and
Henderson, 2012). Much less is known about the effect of HT
administration to younger women starting around the onset of
menopause, although this represents the group potentially
beneﬁtting most from HT treatment according to the critical win-
dow theory.
In humans, the hippocampus is considered a strong predictor for
overall brain health (Wnuk et al., 2012) and is essential for declar-
ative memory (Squire, 1992). AD is associated with hippocampal
pathology (Braak and Braak, 1991), and both hippocampal shape
and volume can predict the onset of AD (Csernansky et al., 2005).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014) and is therefore the preferred structure to investigate for
estrogen-induced neuroprotective effects. Moreover, hippocampal
size is associated with verbal memory performance (Hackert et al.,
2002; O’Driscoll et al., 2001), and recent evidence has shown that
independent of age, menopause is followed by a decline in verbal
memory (Epperson et al., 2013), suggesting a negative effect of
menopause on hippocampal function. The hippocampal volume in
HT users has in observational studies been reported to be larger
(Eberling et al., 2003; Erickson et al., 2005, 2010; Lord et al., 2008)
or not affected (Greenberg et al., 2006; Low et al., 2006) compared
to controls. The only RCT that has assessed the effects of HT on
hippocampal size is the WHIMSemagnetic resonance imaging
(MRI) study, which demonstrated a negative effect on hippocampal
volume when HT was initiated 15e30 years after menopause
(Resnick et al., 2009). The discrepancies between these studies may
be explained by the critical window theory, which posits that a
positive effect on hippocampal structure will be limited to HT taken
around the onset of menopause. Moreover, one study reported that
duration of HT was negatively associated with hippocampal vol-
ume, pointing to a treatment duration effect (Lord et al., 2008).
In contrast to the ambiguous results from human studies, animal
studies have ﬁrmly established beneﬁcial effects of estrogens for
brain physiology, anatomy, and function. For example, rodent
studies in ovariectomized female rats have shown that estradiol
replacement promotes angiogenesis (Barouk et al., 2011) and im-
proves cell proliferation and cell survival in the hippocampus
(Galea et al., 2006). Moreover, estradiol administration increases
spine synapse density on pyramidal cell dendrites in the cornu
ammonis (CA1) subﬁeld of the hippocampus (Woolley and
McEwen, 1992) and restores a more youthful synaptic proﬁle in
the CA1 subﬁeld in normally aging female rats (Adams et al., 2004).
Not only decreased hormone levels but also a lower number of
estrogen receptors is reported in the normally aging female rat,
with a speciﬁc reduction in estrogen receptor positive neurons in
the CA1 subﬁeld (Mehra et al., 2005). This reduction in number of
estrogen receptors has been linked to the diminished cognitive
enhancing effect of HT with increasing age observed in humans
(Foster, 2012) and thus to the critical window theory. Furthermore,
estradiol administration enhances performance on hippocampus-
dependent tasks such as spatial navigation and working memory
in ovariectomized rats (Gibbs, 2000; Luine et al., 1998; Packard and
Teather, 1997). Estrogens are considered to counteract the neuro-
degenerative effects of aging via numerous pathways including
increased expression of genes related to neuroprotection, preser-
vation of neuronal microstructure, synaptic plasticity, and neuro-
genesis, while decreasing the expression of genes related to
inﬂammation, stress, and transcription repressors (Bean et al.,
2014). Estrogens have also been demonstrated to protect against
brain pathology such as AD. In vitro models have shown that
estradiol provides neuroprotection against b-amyloid protein
toxicity (Goodman et al., 1996; Yao et al., 2007) and inhibits
b-amyloid protein accumulation and tau hyperphosphorylation,
crucial components in the development of AD (Pike et al., 2009).
In recent years, techniques for automated brain morphometric
analyses have improved immensely. For example, local volume
differences within hippocampal regions are detectabledeven in
the presence of similar overall volume (Persson et al., 2014). Pre-
vious studies examining the effects of HT on hippocampal volume
have either investigated total volume (Erickson et al., 2010;
Greenberg et al., 2006; Low et al., 2006) or subdivided the hippo-
campus into volumes of interests along its anterior-posterior axis
(Eberling et al., 2003; Erickson et al., 2005). However, the evidence
from rodent studies supports a speciﬁc neuroprotective effect of HT
initiated around menopause in the CA1 subﬁeld, which cannot beidentiﬁed with these methods. We predicted that HT initiated
around onset of menopause would result in larger hippocampal
volume compared with controls and that the volume difference
would be regionally conﬁned to the CA1 subﬁeld. To this end, we
investigated the effects of HT initiated around the onset of meno-
pause on hippocampal volume and shape in a large, community-
based sample of postmenopausal women.
2. Material and methods
The study was approved by the Nord-Trøndelag Health Study
(HUNT) board of directors and the regional ethics and health
research committee (2011/456). All participants gave their
informed written consent.
The HUNT Study is a collaboration between HUNT Research
Centre (Faculty of Medicine, Norwegian University of Science and
Technology NTNU), Nord-Trøndelag County Council, Central Nor-
way Health Authority, and the Norwegian Institute of Public
Health (Krokstad et al., 2013). It is a large multiphase, multipur-
pose health study on the inhabitants 13 years in the county of
Nord-Trøndelag. The inhabitants of Nord-Trøndelag county have
been invited to participate in 3 waves; HUNT1 (1984e86), HUNT2
(1995e97), and HUNT3 (2006e08). The overall participation rates
were 89.4%, 69.5%, and 54.1%, respectively. However, in HUNT3 the
participation rate for women in the age group 60e69 years was
74.5%. A nonparticipation study from HUNT3 showed that non-
participants had lower socioeconomic status, higher mortality,
and higher prevalences of several chronic diseases, whereas
opposite patterns were found for common problems like muscu-
loskeletal pain, urine incontinence, and headache (Langhammer
et al., 2012). HUNT MRI was a substudy after HUNT3. The cohort
invited to participate in HUNT MRI was drawn from the HUNT
population, but limited to volunteers who had participated in
HUNT 1, 2, and 3, and were between 50e65 years at time of in-
clusion in the HUNT MRI study. In total 73% of those invited to
HUNT MRI agreed to participate (Honningsvag et al., 2012). The
HUNT MRI cohort consisted of 1006 subjects (530 women). A
study comparing participants and nonparticipants in the HUNT
MRI study and subjects from the HUNT cohort not invited found
that the groups were not widely different, but HUNT MRI
participating women had a higher level of education, lower body
mass index (BMI), lower blood pressure, but there was no differ-
ence with regard to number of individuals with hypertension, and
fewer had fasting blood glucose  5.6 mmol/L but no difference in
number of diabetic individuals (Honningsvag et al., 2012).
Therewere 175women (33% of all HUNTMRIwomen)whowere
current or past users of HT, 80 (45.7%) of which met the inclusion
criteria which were HT started before menopause and continued at
least for 3 years and through the menopause. Both current and past
users fulﬁlling these criteria were included. These subjects were
thenmatched on intracranial volume (ICV) (5%) and age (1 year)
with 80 never-users of HT from the remaining cohort. Although we
were unable to retrieve information about the precise type of HT
used by each individual, data from the Norwegian Prescription
Registry show that during the time frame of the study and in this
region, 83.5% of HT users were prescribed a combination of estra-
diol and/or estriol and progesterone, 9.0% either estradiol or estriol
without progesterone, and 7.5% used the synthetic estrogen tibo-
lone. Importantly, there were no users of conjugated equine
estrogens.
Information about age, BMI, systolic and diastolic blood pres-
sure, HT (age at onset and duration), age at menarche and meno-
pause, number of pregnancies and births, type of menopause
(surgical and/or natural), as well as a number of comorbidities were
taken from HUNT3 clinical measurement data which was obtained
Fig. 1. Example of hippocampal shape in one HT participant and non-HT participant matched on age and ICV. These hippocampal surface models were used in the vertex-by-vertex
shape analysis, for details see Section 2. Abbreviations: HC, hippocampus; HT, hormone therapy; ICV, intracranial volume.
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were investigated; cerebral insult and hemorrhage, psychological
problems, myocardial infarction, atrial ﬁbrillation, heart failure,
diabetes, epilepsy, asthma, chronic obstructive pulmonary disease
as well as the number of daily and occasional smokers, and the
number of heavy drinkers (>2 drinks per day). Furthermore, self-
reported memory problems were assessed with 9 questions in
HUNT3 based on the metamemory questionnaire (Fromholt and
Berg, 1997). The 2 ﬁrst items asked about memory capacity in
general: “Do you have problems with your memory?” and “Has
your memory changed since you were younger?” The response
categories were “no”, “yes, some”, and “yes, a lot”. The following 7
items were related to performance on speciﬁc memory tasks: “Do
you have problems remembering.”: (1) “. what happened a few
minutes ago”, (2) “. the names of other people”, (3) “. dates”, (4)
“. to carry out planned activities”, (5) “. what happened a few
days ago”, (6) “.what happened some years ago”, and (7) “Do you
have problems keeping track of a conversation”. Response cate-
gories were “never”, “sometimes”, and “often” (Holmen et al.,
2013). There were missing or partial missing data on the self-
reported memory problems in 18 participants. Information on
education (a scale from 1 to 5, 1 ¼ primary school, 2 ¼ high school,
3 ¼ junior college, 4 ¼ university less than 4 years, 5 ¼ university
more than 4 years) was taken from the HUNT2 demographic data.
Imaging was performed on the same 1.5 T General Electric Signa
HDx MRI scanner equipped with an 8-channel head coil (GE
Healthcare) and software version pre-14.0M4. The examinations
were conducted by 8 MRI technologists following a standardized
written and illustrated procedure. In the present study the Alz-
heimer’s disease Neuroimaging Initiate volume, (http://adni.loni.
usc.edu/methods/documents/mri-protocols/) which is a T1-
weighted (T1W) magnetization prepared rapid gradient echo
(MP-RAGE) volume (repitition time ¼ 10.156 ms, echo time ¼
4.044 ms, ﬁeld of view ¼ 240 mm, slice thickness ¼ 1.2 mm, matrix
192  192, ﬂip angle 10) was used.
Thedata setswere analyzedwith FreeSurfer 4.5 (http://surfer.nmr.
mgh.harvard.edu/) for segmentation of the hippocampal volumes
using an automated procedure described previously (Fischl et al.,
2002). To avoid bias, all FreeSurfer results were visually inspected
by a blinded colleague at the Multimodal Imaging Laboratory, Uni-
versity of California, San Diego, where the data analysis wasperformed and all subpar data sets removed. There have been
numerous studies comparing FreeSurfer segmentation with manual
segmentation of hippocampal volumes and the generalﬁnding is that
FreeSurfer segmentation is a reliable option to manual segmentation
(Cherbuin et al., 2009; Doring et al., 2011; Morey et al., 2009; Mulder
et al., 2014; Shen et al., 2010;Wenger et al., 2014). ICV estimationwas
performed in SPM8 (rel. 5236) (http://www.ﬁl.ion.ucl.ac.uk/spm)
using an automated version of the reverse brain mask method
(Keihaninejad et al., 2010) called the “automatic reverse brain mask
method”. Thismethodwasrecently showntohave improvedaccuracy
compared with the ICV estimate generated by FreeSurfer (Hansen
et al., 2015). Right and left hippocampal volume was ICV corrected
using the residuals method (Buckner et al., 2004; Raz et al., 2004).
Reliable manual subﬁeld segmentation based on the current
MP-RAGE volume obtained at 1.5 T is not possible. Automated
subﬁeld segmentation in FreeSurfer is theoretically possible, but
there have been several reports that raise concerns about the val-
idity of this method based on both 1.5 T and 3.0 T standard reso-
lution T1W 3DMRI images (de Flores et al., 2015;Wisse et al., 2014).
We therefore opted for an alternativemethod, which through shape
analysis reﬂects changes in subﬁeld volumes (Patenaude et al.,
2011). We used tools from the FMRIB Software Library 5.0.7 soft-
ware to analyze regional volume changes in the hippocampus
(Smith et al., 2004). Local shape differences were compared
between the 2 groups using a vertex-by-vertex analysis based on
FMRIB’s Integrated Registration and Segmentation Tool (FIRST) 1.2
(Patenaude et al., 2011). First, a surface mesh of the hippocampus in
each subject is created using a deformable mesh model composed
of a set of vertices. The number of vertices in the hippocampus is
ﬁxed so that corresponding vertices can be compared between
groups (Lim et al., 2012a). Examples of the shape analysis for 1 HT
and 1 non-HT subject are shown in Fig. 1. The hippocampal surface
for the right and left hippocampus, respectively, of each participant
were then aligned to an average hippocampus model of left and
right hippocampus, respectively, provided by FIRST using a 6-
degrees of freedom transformation. Group differences in the sur-
face displacement maps were analyzed in FMRIB Software Library
using randomize for nonparametric permutation-based inference
(n¼ 5000) and cluster corrected formultiple comparisons at F> 2.3
(Winkler et al., 2014). The anatomical subﬁelds with signiﬁcant
differences in surface areas between the groups were identiﬁed
Fig. 2. (A) A signiﬁcant volume sparing effect of hormone therapy (HT) was found for the right hippocampus. A nonsigniﬁcant trend was found for the left hippocampus. (B)
Hippocampal subﬁelds mapped onto a model of the right hippocampus, based on the deﬁnitions from Duvernoy, 2005 and West and Gundersen, 1990. The cornu ammonis (CA1)
subﬁeld is colored in orange. (C) A vertex (shape) analysis reveals that the overall volume difference of the right hippocampus was driven by regional sparing of the CA1 and parts of
the subiculum. Orange color indicates areas that are larger in the HT group. The analysis was performed using FIRST, cluster corrected for multiple comparisons, F > 2.3.
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Gundersen, 1990) (Fig. 2B).
Other statistical analyses were performed in SPSS 21.0 (SPSS Inc,
Chicago, Illinois, USA). Statistical outliers were determined using
the outlier labeling rule (Hoaglin and Iglewicz, 1987). A mixed
analysis of variance was run to determine the main effect of HT on
the hippocampal volumes. Subsequently, simple main effects were
investigated using separate between-subjects analyses of variance
for the right and left hippocampus. Independent-sample t tests
were run to determine if there were differences in mean ICV, age,
BMI, age at menarche and menopause, and overall self-reported
memory problem score between the HT and control group,
whereas nonparametric Mann-Whitney U tests were run to deter-
mine if there were group differences in level of education and
number of pregnancies and births. c2 tests were run to assess group
differences in the type of menopause (surgical and/or natural), the
13 comorbidities, and the separate self-reported memory ques-
tions. A corrected p < 0.05 was considered signiﬁcant. Data are
presented as mean  standard deviation, unless otherwise stated.
3. Results
The age range of the included women was 51e66 years. There
was no difference in ICV nor was there any difference in BMI, bloodpressure, education, time at menarche, menopause, number of
pregnancies or births, or type of menopause (surgical and/or nat-
ural) between the 2 groups. The HT group had used estrogen for
7.82  3.43 years (range: 3e15 years) and included 15 current and
65 past users (Table 1). There were no signiﬁcant differences be-
tween the 2 groups on any of the investigated comorbidities
(Table 2). The mean overall self-reported memory problems score
in the HT group (14.26  2.66) was similar to the control group
(13.62  2.80), p ¼ 0.174. Table 3 shows the scores on each self-
reported memory question, no differences between the HT and
control groups were found.
Fig. 2A and Table 1 show the group differences for the ICV cor-
rected hippocampal volumes. The hippocampal volumes were
normally distributed and there were no statistical outliers (Fig. 2A).
The main effect of hormone group demonstrated a statistically
signiﬁcant difference in hippocampal volumes between the 2
groups, F(1,158)¼ 4.932, p¼ 0.028. Both the right (3.627 0.314 vs.
3.511  0.327 mL) and left (3.511  0.351 vs. 3.413  0.301 mL)
hippocampal volumes were larger in the HT group. This difference
was, however, only signiﬁcant for the right hippocampus, F(1,
158) ¼ 5.236, p ¼ 0.023.
Fig. 2C shows the results from the vertex analysis of the right
hippocampus. The orange areas indicate surface areas that were
signiﬁcantly larger in the HT group, cluster corrected for multiple
Table 1
Demographic characteristics and magnetic resonance imagingederived intracranial
and hippocampal volumes of the HT and matched control group
Control group
(n ¼ 80)
HT group
(n ¼ 80)
p-value
Age (y) 59.8  3.6 59.8  3.6 1.000a
BMI (kg/m2) 26.8  4.4 26.7  4.1 0.790a
SBP (mm Hg) 132.2  18.8 130.6  15.1 0.560a
DBP (mm Hg) 74.1  10.8 74.0  10.5 0.934a
Education (group) 2.53  1.48 2.62  1.30 0.693b
Menarche (y) 13.3  1.4 13.3  1.5 0.955a
Menopause (y) 50.0  4.7 50.4  3.1 0.505a
Number of pregnancies 2.9  1.3 2.6  1.2 0.181b
Number of births 2.4  0.9 2.3  0.8 0.332b
Number of participants
with surgical menopause
2 (2.5) 6 (7.5) 0.147c
Age at onset of HT (y) NA 50.0  3.2 NA
Duration of HT (y) NA 7.8  3.4 NA
ICV (mL) 1438.5  96.3 1435.3  98.6 0.833a
Right hippocampal volume (mL) 3.511  0.327 3.628  0.314 0.023d,*
Left hippocampal volume (mL) 3.413  0.301 3.511  0.351 0.060d
*p-value < 0.05.
Education is rated on a scale from 1 to 5, 1 ¼ primary school, 2 ¼ high school, 3 ¼
junior college, 4 ¼ university less than 4 y, 5 ¼ university more than 4 y. Data are
presented as mean  standard deviation or as n with (%) for surgical menopause.
Key: BMI, body mass index; DBP, diastolic blood pressure; HT, hormone therapy;
ICV, intracranial volume; NA, not applicable; SBP, systolic blood pressure.
a Group differences assessed with independent samples t tests.
b Group differences assessed with nonparametric Mann-Whitney U test.
c Group differences assessed with c2 test.
d Group differences assessed with between-subjects analysis of variance.
Table 3
Prevalence of 9 items of self-reported memory problems in the HT and matched
control group
Control group HT group p-
value
Some Great Some Great
Problems with memory (%) 49.2 0 53.2 1.3 0.568
Memory changed (%) 70.8 4.6 78.5 10.1 0.071
Sometimes Often Sometimes Often
Problems remembering minutes
ago (%)
17.2 0 17.9 0 0.906
Problems remembering names (%) 71.4 14.3 81.3 13.8 0.150
Problems remembering dates (%) 57.1 4.8 66.3 5.0 0.494
Problems remembering plans (%) 25.0 0 27.8 0 0.701
Problems remembering days
ago (%)
28.6 3.2 43.8 0 0.062
Problems remembering years
ago (%)
57.8 6.3 73.8 3.8 0.131
Problems keeping track of
conversation (%)
15.4 0 26.3 0 0.112
Data are presented as %. Group differences assessed with c2 test. A corrected p-value
of 0.0055 (0.05/9) was considered signiﬁcant.
Key: HT, hormone therapy.
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HTon the right hippocampal volumewas driven by regional sparing
of the medial aspect of the head and lateral aspect of the body
extending to the tail, corresponding to the CA1 subﬁeld and
including part of the subiculum. The assignment of the shape
changes to these hippocampal subﬁelds was based on anatomical
knowledge (Fig. 2B). No statistically signiﬁcant difference in the left
hippocampal shape was detected between the 2 groups, although a
similar pattern was observed below the predeﬁned statistical
threshold.4. Discussion
In the present study, we demonstrate a positive effect of peri-
menopausal HT on hippocampal volume in a large, general popu-
lation based, well-matched sample of women aged 51e66 years.
The volume sparing effect of HT was shown to be regionallyTable 2
Prevalence of comorbidities in the HT and matched control group
Control group (n ¼ 80) HT group (n ¼ 80) p-value
Cerebral insult 4 (5.0) 1 (1.3) 0.173
Cerebral hemorrhage 4 (5.0) 2 (2.5) 0.405
Psychological problems 16 (20.0) 21 (26.3) 0.348
Myocardial infarction 1 (1.3) 0 (0) 0.316
Atrial ﬁbrillation 1 (1.3) 0 (0) 0.316
Heart failure 0 (0) 0 (0) 1.000
Diabetes 2 (2.5) 2 (2.5) 1.000
Epilepsy 1 (1.3) 0 (0) 0.316
Asthma 6 (7.5) 8 (10.0) 0.576
COPD 1 (1.3) 0 (0) 0.316
Daily smokers 17 (21.3) 15 (18.8) 0.693
Occasional smokers 6 (7.5) 8 (10.0) 0.576
Heavy drinkers 1 (1.3) 2 (2.5) 0.560
Data are presented as n (%). Group differences assessed with c2 test. A corrected
p-value of 0.0038 (0.05/13) was considered signiﬁcant.
Key: COPD, chronic obstructive pulmonary disease; HT, hormone therapy.conﬁnedmainly to the CA1 subﬁeld andwas signiﬁcant for the right
side only.
We found increased hippocampal volume in the medial aspect
of the head and lateral aspect of the body extending to the tail,
approximately corresponding to the CA1 subﬁeld, including part of
the subiculum. This pattern of hippocampal subﬁeld volume loss in
the nonHT group compared to the HT group, is strikingly similar to
the hippocampal volume loss reported in numerous imaging
studies comparing AD or mild cognitive impairment (MCI) patients
with matched controls (Apostolova et al., 2006; Gerardin et al.,
2009; Lim et al., 2012b; Seidl et al., 2012). Moreover, histopatho-
logical studies have demonstrated that these hippocampal sub-
ﬁelds are predominantly affected in AD (Hyman et al., 1984; Van
Hoesen and Hyman, 1990). The shape in the areas corresponding
to the CA2 and CA3 subﬁelds were similar in the HT compared with
the non-HT group, which is consistent with both histopathological
(Hyman et al., 1984; Van Hoesen and Hyman, 1990) and imaging
(Frisoni et al., 2006) ﬁndings in AD patients. Signiﬁcant volume
sparing effects of HT was found in the right hippocampus only,
although a similar volume sparing pattern was observed in the left
hippocampus below the predeﬁned statistical threshold (results
not shown). A more marked effect of HT on the right hippocampus
is in-line with several of the previous observational HT studies
(Eberling et al., 2003, 2004; Lord et al., 2008). Moreover, an
asymmetrical atrophy rate with faster volume loss in the right
hippocampus has been shown during the transition from healthy to
MCI and from MCI to AD, for review see Shi et al., 2009. Indeed, a
strong correlation between hippocampal volume and CA1 neuron
loss has been demonstrated in both AD patients and normal aging
(Kril et al., 2004), suggesting that the larger hippocampal volume in
the present study represents an actual neuroprotective effect of HT.
Taken together, we have demonstrated a localized volume sparing
effect of HT on the right hippocampal CA1 subﬁeld, an area that is
affected in the development of MCI and AD.
In the present study, the HT group had used HT for a relative
short time (mean 7.8 years). Previous studies that report positive
effects of HT on hippocampal volumes report somewhat longer HT
duration than our study (w12.0, 14.3, and 10.5 years) (Erickson
et al., 2005, 2010; Lord et al., 2008), whereas 1 study that found a
negative effect of HT on gray matter volumes had a very long mean
duration of treatment (23.5 years) (Greenberg et al., 2006). It has
further been shown that the duration of HT is negatively associated
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that is, that HT is only beneﬁcial for a limited time after menopause
(Lord et al., 2008). Consistent with our results,1 observational study
found an association between HT initiated coincidentally with
menopause and larger overall hippocampal volume, whereas no
difference in hippocampal volume was found when HT was initi-
ated several years after menopause (Erickson et al., 2010). The only
RCT that has assessed the effects of HT on hippocampal volume
demonstrated a negative effect when HT was initiated 15e30 years
after menopause (Resnick et al., 2009). Moreover, no group differ-
ence was found in the mean self-reported memory score in the
present study, and both groups’ self-reported memory score was
comparable to the results found in a larger sample from the HUNT
cohort (Holmen et al., 2013). The WHIMS of younger women clin-
ical trial found neither beneﬁcial nor harmful effects of 7 years of
HT on several cognitive measures. Although the participants in
WHIMS of younger women were younger than in the original
WHIMS study, the mean time betweenmenopause and initiation of
HT was 7 years (Espeland et al., 2013). Likewise, preliminary results
from the Kronos Early Estrogen Prevention Study assessing the ef-
fects of HT started within 3 years after menopause indicate neither
beneﬁcial nor harmful effects of HT on tests of cognition. Impor-
tantly, neither of these studies investigated the effects of HT started
before the menopause, but rather several years after, and thus
outside the hypothesized critical window.
Some limitations should be noted. First, the vertex analysis for
demonstration of hippocampal shape differences is performed on
the whole hippocampus, and no subﬁeld segmentation was per-
formed. Thus, the anatomical localization of the differences in
surface anatomy between the groups relies on anatomical
knowledge (Duvernoy, 2005; West and Gundersen, 1990). To date,
no validation study has been performed that compares local shape
differences with volumetric measurement of the underlying sub-
ﬁeld. Although shape analysis cannot be compared directly to
either manual or automatically derived subﬁeld volumetric mea-
surements, it provides similar and sometimes more information.
Indeed, a recent study in early-stage Parkinson’s patients
demonstrated that disease-related structural change was unde-
tectable when investigating overall regional volume but could be
identiﬁed with shape analysis (Menke et al., 2014). Furthermore,
in disorders where hippocampal atrophy does not occur uni-
formly, localized shape differences can be detected despite com-
parable overall subﬁeld volume. For example, a study by
Costafreda et al. (2011) investigated the hippocampal shape in a
group of 103 MCI subjects acquired with 1.5 T using the Alz-
heimer’s disease Neuroimaging Initiate protocol (Costafreda et al.,
2011). Using hippocampal shape abnormalities they were able to
predict 1-year conversion to AD with an accuracy of 80% and the
pattern of atrophy associated with increased risk of conversion to
AD was localized to the anterior part of the CA1. Moreover, using
hippocampal shape to predict the conversion to AD was found to
be comparable or superior to volumetric models. This study clearly
demonstrates that even in MRI images with limited resolution,
shape analysis cannot only pinpoint differences to hippocampal
subﬁelds but also predict future disease, thus demonstrating that
detected shape differences represent relevant pathological pro-
cesses. The shape analysis method has also been successfully used
on both 1.5 T and 3.0 T standard resolution T1W 3D MRI images to
address the impact of AD and MCI (Lim et al., 2012a, 2012b; Seidl
et al., 2012), normal aging (Jiang et al., 2014; Thomann et al., 2013),
temporal lobe epilepsy (Mumoli et al., 2013), multiple sclerosis
(Gold et al., 2014), puberty (Satterthwaite et al., 2014), Niemann-
Pick disease (Walterfang et al., 2013), and erythropoietin
(Miskowiak et al., 2014) on the shape of the hippocampus and its
subﬁelds.Furthermore, we did not differentiate between current and past
users of HT. Whether HT has transient or lasting neuroprotective
effects remains unknown. One study reported an effect of time
since HT use on hippocampal volume (Lord et al., 2008), but most
studies have grouped current and past users and reported beneﬁcial
effects of HT on brain structure (Erickson et al., 2005, 2010). Finally,
HT users were identiﬁed by means of self-report, and no informa-
tion about exact type or dose was registered at the individual level.
However, HT users in Norway and in this region, as established
through the Norwegian Prescription Registry, take primarily
estradiol and/or estriol with progesterone, rather than conjugated
equine estrogens, which are widely used in the United States. The
results, thus, point to a positive effect of perimenopausal HT in
general on hippocampal volume, which may be further potentiated
with more tailored drugs.
The main strengths of the study include a large, ICV- and age-
matched population-based sample with a narrow age range.
There are several methods to correct for ICV differences and
consensus is lacking on which method to use. Indeed, amongst the
previous studies investigating the effects of HT on hippocampal
volume none were matched on ICV, and several different ICV
correction methods have been used including the proportions
method (Eberling et al., 2003), the residuals method (Erickson et al.,
2010), analysis of covariance (Resnick et al., 2009), or no ICV
correction at all (Lord et al., 2008). A recent study comparing
different ICV correction methods report a signiﬁcant effect of
methodwhen investigating the impact of sex and aging on different
cortical and subcortical volumetric measures (Voevodskaya et al.,
2014). By matching the subjects on ICV this possible confounder
is eliminated. To the best of our knowledge, only 2 previous studies
investigating the effects of HT on hippocampal volumes have been
performed on general population-based samples (Eberling et al.,
2003; Low et al., 2006), both performed in older women than
here, and less stringently described cohorts. The HUNT MRI study
had a participation rate of 73%, and participants were drawn from
the HUNT study, a longitudinal population health study in Norway,
where participation for the age range invited here is also >70%
(Honningsvag et al., 2012). A participation rate of >70% is accept-
able and increases the probability of representativeness (Stovner
et al., 2014). In contrast, the use of volunteers in cross-sectional
studies can be problematic as they are unlikely to be representa-
tive of the general population (Mann, 2003).
5. Conclusions
The present study supports the hypothesis that HT initiated
around the onset of menopause has neuroprotective properties. We
further demonstrate, for the ﬁrst time, regional sparing conﬁned
mainly to the CA1 subﬁeld of the right hippocampus, an area that is
closely linked to the development of MCI and AD.
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